Cargando…
Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
BACKGROUND: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docet...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676758/ https://www.ncbi.nlm.nih.gov/pubmed/29152553 http://dx.doi.org/10.3233/BLC-170126 |
_version_ | 1783277119534530560 |
---|---|
author | Milbar, Niv Kates, Max Chappidi, Meera R. Pederzoli, Filippo Yoshida, Takahiro Sankin, Alexander Pierorazio, Phillip M. Schoenberg, Mark P. Bivalacqua, Trinity J. |
author_facet | Milbar, Niv Kates, Max Chappidi, Meera R. Pederzoli, Filippo Yoshida, Takahiro Sankin, Alexander Pierorazio, Phillip M. Schoenberg, Mark P. Bivalacqua, Trinity J. |
author_sort | Milbar, Niv |
collection | PubMed |
description | BACKGROUND: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). OBJECTIVE: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies. METHODS: Thirty-three patients who received full induction GEM/DOCE since 2011, per the protocol adapted from U. Iowa, were identified and characterized. Multivariable logistic regression was used to determine factors associated with recurrence. Cox proportional hazard models evaluated risk factors for disease-free survival (DFS) and high-grade recurrence-free survival (HG-RFS). RESULTS: There were no serious adverse effects of therapy. Across all patients, median follow-up time was 18.6 months with a median DFS of 6.5 months, 42% 1-year, and 24% 2-year DFS. Median HG-RFS was 17.1 months with 56% 1-year and 42% 2-year HG-RFS. Among patients initially presenting with HG-NMIBC, 46% (13/28) had HG recurrence. BCG unresponsive/relapsing patients (N = 25) displayed 49% 1-year HG-RFS and 34% 2-year HG-RFS. In total, there were 5 LG and 16 HG recurrences, with 5 progressions and 8 cystectomies among these. CONCLUSIONS: GEM/DOCE is a well-tolerated therapy that deserves further study as an alternative to immediate RC for highly selected patients with HG-NMIBC. BCG naïve patients responded more effectively than BCG unresponsive/relapsing patients. As anticipated, GEM/DOCE efficacy was improved for HG only patients. |
format | Online Article Text |
id | pubmed-5676758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56767582017-11-16 Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer Milbar, Niv Kates, Max Chappidi, Meera R. Pederzoli, Filippo Yoshida, Takahiro Sankin, Alexander Pierorazio, Phillip M. Schoenberg, Mark P. Bivalacqua, Trinity J. Bladder Cancer Research Report BACKGROUND: Bacillus Calmette-Guérin (BCG) unresponsive/relapsing patients with non-muscle invasive bladder cancer (NMIBC) who prefer bladder preservation over radical cystectomy (RC) or those who do not qualify for surgery may be offered intravesical therapies. Gemcitabine (GEM) combined with Docetaxel (DOCE) has been offered at Johns Hopkins Hospital (JHH). OBJECTIVE: To evaluate experience with GEM/DOCE, to confirm safety of the regimen, to identify populations that may benefit most, and to consider the appropriate endpoints for judging efficacy of second line therapies. METHODS: Thirty-three patients who received full induction GEM/DOCE since 2011, per the protocol adapted from U. Iowa, were identified and characterized. Multivariable logistic regression was used to determine factors associated with recurrence. Cox proportional hazard models evaluated risk factors for disease-free survival (DFS) and high-grade recurrence-free survival (HG-RFS). RESULTS: There were no serious adverse effects of therapy. Across all patients, median follow-up time was 18.6 months with a median DFS of 6.5 months, 42% 1-year, and 24% 2-year DFS. Median HG-RFS was 17.1 months with 56% 1-year and 42% 2-year HG-RFS. Among patients initially presenting with HG-NMIBC, 46% (13/28) had HG recurrence. BCG unresponsive/relapsing patients (N = 25) displayed 49% 1-year HG-RFS and 34% 2-year HG-RFS. In total, there were 5 LG and 16 HG recurrences, with 5 progressions and 8 cystectomies among these. CONCLUSIONS: GEM/DOCE is a well-tolerated therapy that deserves further study as an alternative to immediate RC for highly selected patients with HG-NMIBC. BCG naïve patients responded more effectively than BCG unresponsive/relapsing patients. As anticipated, GEM/DOCE efficacy was improved for HG only patients. IOS Press 2017-10-27 /pmc/articles/PMC5676758/ /pubmed/29152553 http://dx.doi.org/10.3233/BLC-170126 Text en © 2017 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Report Milbar, Niv Kates, Max Chappidi, Meera R. Pederzoli, Filippo Yoshida, Takahiro Sankin, Alexander Pierorazio, Phillip M. Schoenberg, Mark P. Bivalacqua, Trinity J. Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer |
title | Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer |
title_full | Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer |
title_fullStr | Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer |
title_full_unstemmed | Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer |
title_short | Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer |
title_sort | oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676758/ https://www.ncbi.nlm.nih.gov/pubmed/29152553 http://dx.doi.org/10.3233/BLC-170126 |
work_keys_str_mv | AT milbarniv oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT katesmax oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT chappidimeerar oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT pederzolifilippo oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT yoshidatakahiro oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT sankinalexander oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT pieroraziophillipm oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT schoenbergmarkp oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer AT bivalacquatrinityj oncologicaloutcomesofsequentialintravesicalgemcitabineanddocetaxelinpatientswithnonmuscleinvasivebladdercancer |